NextPlat (NXPL) Cash & Equivalents Growth (5y) (2019 - 2026)
Powered by 
Analysis
NextPlat (NXPL) Cash & Equivalents Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.70% |
| Mar 31, 2026 | 81.47% |
| Dec 31, 2025 | 79.84% |
| Sep 30, 2025 | 76.33% |
| Jun 30, 2025 | 120.86% |
| Mar 31, 2025 | 164.09% |
| Dec 31, 2024 | 205.21% |
| Sep 30, 2024 | 194.93% |
| Jun 30, 2024 | 137.32% |
| Mar 31, 2024 | 192.55% |
| Dec 31, 2023 | 183.80% |
| Sep 30, 2023 | 164.52% |
| Jun 30, 2023 | 114.66% |
| Mar 31, 2023 | 138.53% |
| Dec 31, 2022 | 140.80% |
| Sep 30, 2022 | 115.51% |
| Jun 30, 2022 | 109.96% |
| Mar 31, 2022 | 152.25% |
| Dec 31, 2021 | 172.59% |
| Sep 30, 2021 | 170.54% |